Efficacy of ifosfamide, methotrexate, etoposide and prednisone (IMEP) chemotherapy in extranodal NK/T-cell lymphoma, nasal type.

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Meetings

Abstracts

2004 ASCO Annual Meeting

Efficacy of ifosfamide, methotrexate, etoposide and prednisone (IMEP) chemotherapy in extranodal NK/T-cell lymphoma, nasal type.

Sub-category:

Lymphoma

Category:

Adult Leukemia, Lymphoma and Transplantation

Meeting:

2004 ASCO Annual Meeting

Abstract No:

6685

Citation:

Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 6685

Author(s):

K. W. Lee, D. W. Kim, S. A. Im, T. Y. Kim, S. S. Yoon, D. S. Heo, Y. J. Bang, S. Park, B. K. Kim, N. K. Kim; Seoul National University Hospital, Seoul, Republic of Korea

Abstract:

Background: Although most patients diagnosed with extranodal NK/T-cell lymphoma, nasal type (ENNKTL) have localized disease, radiation therapy alone is not satisfactory because of frequent systemic failure. Also, when compared with B-cell lymphomas, ENNKTL have poor response to conventional doxorubicin-based chemotherapy. Therefore, more effective chemotherapeutic regimens are required. Methods: Patients with histologically confirmed ENNKTL were included. All patients received IMEP chemotherapy as first-line treatment (ifosfamide 1.5 g/m² i.v. with mesna supplement on days 1-3; methotrexate 30 mg/m² i.v. push on days 3 and 10; etoposide 100 mg/m² i.v. on days 1-3; and prednisone 120 mg p.o. on days 1-5). Radiation therapy was used only in patients of Ann Arbor stage I or II developing local failure. Results: Since June 2001, 21 ENNKTL patients were enrolled. Of these patients, 15 patients had nasal localization (Ann Arbor stage I or II) and 6 patients had extranasal or disseminated disease. Median follow-up duration was 9.9 (3.5~30.0) months. Overall complete remission (CR) rate was 66.7%. Among patients with nasal localization (stage I or II), 11 had CR (84.6%). Of these patients with CR, 3 patients (27.3%) developed recurrence, but this was successfully controlled with additional radiotherapy. However, patients with extranasal or disseminated disease had poor response (CR: 20.0%). Conclusions: IMEP regimen in patients with ENNKTL was effective as first-line therapy, especially in the cases with nasal localization.

Extranodal NK/T-cell lymphoma, nasal type (N = 21)	Complete Remission (in evaluable patients)
Nasal localization [Stage I, II] (N = 15)	11 / 13 (84.6 %)
Extranasal localization (N = 6)	1 / 5 (20.0 %)

Associated Presentation(s):

No items found.

Other Abstracts in this Sub-Category:

		1. Impact of response to chemotherapy and treating institution on survival in primary CNS lymphoma (PCNSL): Long-term results of the multicenter BMPD study. Meeting: 2004 ASCO Annual Meeting Abstract No: 1522 First Author: A. Korfel Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma
		2. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. Meeting: 2004 ASCO Annual Meeting Abstract No: 6500 First Author: M. G. Pfreundschuh Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma
		3. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Meeting: 2004 ASCO Annual Meeting Abstract No: 6501 First Author: W. Hiddemann Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma
		More...

Abstracts by K. W. Lee:

		1. EGFR mutation and intron 1 CA repeat polymorphism as predictive markers of gefitinib responsiveness in non-small cell lung cancer (NSCLC). Meeting: 2006 ASCO Annual Meeting Abstract No: 7173 First Author: S. W. Han Category: Lung Cancer - Non-Small Cell Lung Cancer
		2. Phase II Study of Low-dose Paclitaxel and Cisplatin as Second-line Therapy in 5-Fluorouracil and Platinum Pretreated Gastric Cancer Meeting: 2005 ASCO Annual Meeting Abstract No: 4194 First Author: K. W. Lee Category: Gastrointestinal (Noncolorectal) Cancer - Esophageal, Gastric, or Small Bowel Cancer
		3. Efficacy of ifosfamide, methotrexate, etoposide and prednisone (IMEP) chemotherapy in extranodal NK/T-cell lymphoma, nasal type. Meeting: 2004 ASCO Annual Meeting Abstract No: 6685 First Author: K. W. Lee Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma
		More...

Presentations by K. W. Lee:

No items found.

Educational Book Manuscripts by K. W. Lee:

No items found.